These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7996546)

  • 1. Bioreductive markers for hypoxic cells: 2-nitroimidazoles with biotinylated 1-substituents.
    Hodgkiss RJ; Parrick J; Porssa M; Stratford MR
    J Med Chem; 1994 Dec; 37(25):4352-6. PubMed ID: 7996546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgehead-nitrogen, bicyclic systems.
    Hodgkiss RJ; Middleton RW; Parrick J; Rami HK; Wardman P; Wilson GD
    J Med Chem; 1992 May; 35(10):1920-6. PubMed ID: 1588568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of bioreductive markers for tumour hypoxia.
    Hodgkiss RJ; Webster L; Wilson GD
    Acta Oncol; 1995; 34(3):351-5. PubMed ID: 7779422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent markers for hypoxic cells: a study of nitroaromatic compounds, with fluorescent heterocyclic side chains, that undergo bioreductive binding.
    Hodgkiss RJ; Jones GW; Long A; Middleton RW; Parrick J; Stratford MR; Wardman P; Wilson GD
    J Med Chem; 1991 Jul; 34(7):2268-74. PubMed ID: 2066999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel intravascular drug delivery method using endothelial biotinylation and avidin-biotin binding.
    Hoya K; Guterman LR; Miskolczi L; Hopkins LN
    Drug Deliv; 2001; 8(4):215-22. PubMed ID: 11757779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
    Hodgkiss RJ
    Anticancer Drug Des; 1998 Sep; 13(6):687-702. PubMed ID: 9755725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
    Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
    Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
    Hodgkiss RJ; Stratford MR; Dennis MF; Hill SA
    Br J Cancer; 1995 Dec; 72(6):1462-8. PubMed ID: 8519660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers.
    Koch CJ; Giandomenico AR; Iyengar CW
    Biochem Pharmacol; 1993 Sep; 46(6):1029-36. PubMed ID: 8216345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of endogenous biotin on the applications of streptavidin and biotin in mice.
    Rusckowski M; Fogarasi M; Fritz B; Hnatowich DJ
    Nucl Med Biol; 1997 Apr; 24(3):263-8. PubMed ID: 9228661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.
    Dou S; Virostko J; Greiner DL; Powers AC; Liu G
    Mol Pharm; 2015 Aug; 12(8):3097-103. PubMed ID: 26103429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity.
    Zhang X; Su ZF; Ballinger JR; Rauth AM; Pollak A; Thornback JR
    Bioconjug Chem; 2000; 11(3):401-7. PubMed ID: 10821657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
    Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
    J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid estimation of avidin and streptavidin by fluorescence quenching or fluorescence polarization.
    Kada G; Kaiser K; Falk H; Gruber HJ
    Biochim Biophys Acta; 1999 Mar; 1427(1):44-8. PubMed ID: 10082986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake by macrophages of a biotinylated oligo-alpha-deoxythymidylate by using mannosylated streptavidin.
    Bonfils E; Mendes C; Roche AC; Monsigny M; Midoux P
    Bioconjug Chem; 1992; 3(4):277-84. PubMed ID: 1390982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.
    Olive PL; Durand RE; Raleigh JA; Luo C; Aquino-Parsons C
    Br J Cancer; 2000 Dec; 83(11):1525-31. PubMed ID: 11076663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation.
    Hirsch JD; Eslamizar L; Filanoski BJ; Malekzadeh N; Haugland RP; Beechem JM; Haugland RP
    Anal Biochem; 2002 Sep; 308(2):343-57. PubMed ID: 12419349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in tumor hypoxia measured with a double hypoxic marker technique.
    Ljungkvist AS; Bussink J; Rijken PF; Raleigh JA; Denekamp J; Van Der Kogel AJ
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1529-38. PubMed ID: 11121659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods.
    Bratthauer GL
    Methods Mol Biol; 2010; 588():257-70. PubMed ID: 20012837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation of avidin-based tumor pretargeting with DOTA-Triazole-Biotin constructed via versatile Cu(I) catalyzed click chemistry.
    Uppal JK; Varshney R; Hazari PP; Chuttani K; Kaushik NK; Mishra AK
    J Drug Target; 2011 Jul; 19(6):418-26. PubMed ID: 20678008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.